CRP and COVID-19: This is underscored by recent studies in patients with severe coronavirus disease 2019 (COVID-19) in which C-reactive protein (CRP) and soluble urokinase plasminogen receptor (suPAR) plasma levels were successfully used to guide treatment with respectively anti-interleukin (IL)-6 and anti-IL-1 [13, 14].